Federal Register of Legislation - Australian Government

Primary content

PB 33 of 2019 Determinations/Health as made
This instrument amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010) by adding to F1 three new drugs – avelumab, inotuzumab ozogamicin, and palbociclib. It also removes one drug from F1 – clodronic acid as this drug is no longer Pharmaceutical Benefits Scheme listed.
Administered by: Health
Registered 30 Apr 2019
Tabling HistoryDate
Tabled HR02-Jul-2019
Tabled Senate02-Jul-2019
Date of repeal 17 Sep 2019
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

 

PB 33 of 2019

 

I, SEAN LANE, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.

Dated            29  April 2019

 

 

 

 

 

 

 

 

 

SEAN LANE

 

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 

 

 

 

Part 1         Preliminary

1              Name of Determination

         (1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2019 (No. 4).

         (2)   This Determination may also be cited as PB 33 of 2019.

2              Commencement

                This Determination commences on 1 May 2019.

3              Amendment of National Health (Listed drugs on F1 or F2) Determination 2010

                Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).


Schedule 1             Amendments

 

(Section 3)

 

[1]     Schedule 1, after item dealing with Aurothiomalate

 

Insert

Avelumab

 

[2]     Schedule 1, after item dealing with Clobetasol

 

Omit

Clodronic acid

 

[3]     Schedule 1, after item dealing with Indacaterol

 

Insert

Inotuzumab ozogamicin

 

[4]     Schedule 1, after item dealing with Paclitaxel, nanoparticle albumin-bound

 

Insert

Palbociclib